Question Bank › Ground-level proof points accumulating

Ground-level proof points accumulating

Ground-level proof points accumulating: management narrates several small, named, recent wins and treats them as the lea

Calls Tested
322
Answered YES
8
Hit Rate
2.5%
rare by design

Fate Therapeutics, Inc. (FATE) — this company's answers

NO on the Q3 2016 call 2016-11-07 C
The model's full reasoning — Q3 2016 call → NO我们根据提供的电话会议记录来判断。管理层提到了多个具体事件:ProTmune临床试验方案修改并开始入组,FATE-NK100提交IND,ToleraCyte获得FDA积极反馈,与纪念斯隆凯特琳合作,以及多个监管指定(快速通道、孤儿药)。这些是具体事件。管理层也将其描述为进展,并说“substantial progress”和“intensified our clinical commitment”,但需要看是否明确将这些事件连接成一个更广泛的早期模式。管理层说“we have delivered substantial progress and intensified our clinical commitment to each of our programs”,并列举了这些事件。但模式是否“still early”?管理层提到“we have now initiated clinical translation of our first off-the-shelf product candidate”等,但整体上,这些事件是独立的进展,管理层没有明确说“这些是更大趋势的开始,更多即将到来”这样的表述。他们确实说“we believe we are well-positioned to rapidly deliver robust results”等,但更多是展望。另外,这些事件是近期发生的,但管理层是否将它们视为“leading edge of a broader improvement that is still early”?在ProTmune部分,他们提到“we believe that with the implementation of this protocol amendment we are well-positioned to rapidly deliver robust results that can enable confident decision-making and potentially support an accelerated registration strategy” — 这有点连接。但整体上,管理层没有明确说“这些是早期迹象,更多正在形成”。他们更多是报告进展。另外,注意问题要求“management explicitly treats these accumulating episodes as the LEADING EDGE of a broader improvement that is still early”。管理层在总结时说“Over the past several months we have delivered substantial progress and intensified our clinical commitment to each of our programs.” 然后列举了具体事件,但并没有明确说“这些是更广泛改进的前沿,且仍处于早期”。他们确实说“we have the opportunity to be the first group to ever advance an engineered iPSC-derived cancer immunotherapy into clinical development”等,但那是关于未来的。我认为管理层没有明确地将这些具体事件连接成一个“still early”的模式。他们只是报告了进展。另外,这些事件是否都是“ground-level wins”?是的,比如IND提交、临床试验方案修改、合作等。但问题要求“management explicitly connects the episodes into a building pattern that is still early”。管理层在最后说“we have made substantial progress and intensified our clinical commitment”但并没有说“这些是早期迹象,更多即将到来”。他们确实说“we look forward to discussing with the FDA our path to become the first group to advance an engineered induced pluripotent cell line derived cancer immunotherapy into clinical development” — 那是未来计划。所以我认为答案可能是NO,因为管理层没有明确地将这些事件连接成一个更广泛的早期模式。他们只是报告了各个进展。另外,注意问题要求“management itself connects the episodes into a building pattern that is still early”。在电话中,管理层没有说“这些事件表明我们正在进入一个更大的趋势”之类的。他们只是说“we have delivered substantial progress”。所以我认为答案是否定的。但让我们再仔细看:在ProTmune部分,Chris说“we believe that with the implementation of this protocol amendment we are well-positioned to rapidly deliver robust results that can enable confident decision-making and potentially s

← Back to the full FATE analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from inside the business, each one identifiable on its own — AND does management explicitly treat these accumulating episodes as the LEADING EDGE of a broader improvement that is still early? Answer YES when BOTH halves come through in management's own words, in whatever form fits the business: (1) AT LEAST THREE DISTINCT, NAMED OR INDIVIDUALLY IDENTIFIABLE EPISODES FROM THE RECENT PERIOD. Management recounts multiple separate ground-level events that actually happened recently — each described specifically enough that a listener could tell the episodes apart and could later check them. The episodes may take whatever form fits the industry: a particular customer, account, or partner that signed, reordered, expanded, or went live; a particular site, store, plant, line, rig, clinic, or facility that opened, hit a milestone, or reached a new performance level; a particular product, program, or offering that shipped its first units, won its first placements, or crossed a threshold; a particular region, channel, or contract that turned on or stepped up. What matters is the GRANULARITY and RECENCY: these are individually small, freshly occurred, operator-level facts — the kind of detail only people close to the business would narrate — not aggregate results, percentages, themes, or claims like "demand was strong across the board." (2) MANAGEMENT ITSELF CONNECTS THE EPISODES INTO A BUILDING PATTERN THAT IS STILL EARLY. Management explicitly draws the line from these individual episodes to a larger developing trajectory — conveying, in its own voice, that these wins are instances of the same underlying thing, that more of the same kind are already forming or arriving, and that the pattern's contribution to reported results is only beginning, so most of it lies ahead. The generalization must be management's own act, grounded in the recounted episodes — not a hope, a market-size claim, or an analyst's summary. Answer NO if the call's positive story is carried mainly by aggregates — overall growth rates, segment percentages, or general demand commentary — without several individually identifiable recent episodes. NO if fewer than three distinct episodes are described, or the episodes are really one event told from different angles. NO if the episodes are plans, pipeline items, letters of intent, or hoped-for events rather than things that already happened. NO if the episodes are the routine cadence this company always reports (its usual pace of customer additions, standard seasonal openings) and management does not present their accumulation as new or building. NO if management recounts the episodes but never itself connects them into a broader, still-early pattern with more arriving. NO if the episodes chiefly explain problems, or the call is mainly defense of weak results. NO if the pattern-framing appears only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
MBLY Mobileye Global Inc. Q2 2023 2023-07-28 B+
TOST Toast, Inc. Q4 2022 2023-02-16 C+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

AU · Q2 2018 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple specific, recent operational episodes: Kibali’s underground ramp-up with automated ore handling system and vertical shaft integration; Iduapriem’s CIL tank conversion and grade/tonnage gains; Sunrise Dam’s Recovery Enhancement Project plus new mining strategies; Tropicana’s second 6-MW ball mill installation; Siguiri’s CIL circuit milestone; and 338 tracked Operational Excellence projects.
BXP · Q1 2022 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple distinct, named episodes from the recent period: the 73,000 sq ft recapture/release at 77 CityPoint with a 15% rent increase and 7.
CRGO · Q1 2024 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...

More from the question bank

Conversion calendar in handFresh order-of-magnitude reference changeBetting on a customer they cannot yet nameOutside actors already movingWinning more per swing than they used to — aPriced for a smaller companyAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.